Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H. Anastasiou OE, et al. Among authors: luth s. J Viral Hepat. 2021 Feb;28(2):410-419. doi: 10.1111/jvh.13439. Epub 2020 Dec 12. J Viral Hepat. 2021. PMID: 33185325 Clinical Trial.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: luth s. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Wedemeyer H, et al. Among authors: luth s. Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7. Lancet Infect Dis. 2019. PMID: 30833068 Clinical Trial.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Bremer B, et al. Among authors: luth s. Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. Liver Int. 2021. PMID: 33217778
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity.
Deterding K, Grüner N, Buggisch P, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Grohennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, Wiegand J; Hep-Net Acute HCV-III Study Group. Deterding K, et al. Among authors: luth s. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):187-92. doi: 10.1097/MEG.0000000000000517. Eur J Gastroenterol Hepatol. 2016. PMID: 26575158 Clinical Trial.
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; Hep-Net Acute HCV-III Study Group. Deterding K, et al. Among authors: luth s. Lancet Infect Dis. 2013 Jun;13(6):497-506. doi: 10.1016/S1473-3099(13)70059-8. Epub 2013 Mar 22. Lancet Infect Dis. 2013. PMID: 23523674 Clinical Trial.
Exacerbation of hepatitis E virus infection during anti-TNFα treatment.
Behrendt P, Lüth S, Dammermann W, Drave S, Brown RJ, Todt D, Schnoor U, Steinmann E, Wedemeyer H, Pischke S, Iking-Konert C. Behrendt P, et al. Among authors: luth s. Joint Bone Spine. 2017 Mar;84(2):217-219. doi: 10.1016/j.jbspin.2016.09.017. Epub 2016 Nov 8. Joint Bone Spine. 2017. PMID: 27836355
High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
Bockmann JH, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall MT, Murray JM, Dandri M, Lüth S, Lohse AW, Lütgehetmann M, Schulze Zur Wiesch J. Bockmann JH, et al. Among authors: luth s. BMC Gastroenterol. 2020 Jan 30;20(1):24. doi: 10.1186/s12876-020-1168-9. BMC Gastroenterol. 2020. PMID: 32000689 Free PMC article.
87 results